Interstitial Lung Disease Market projected to experience notable expansion at a CAGR of 8.7% between 2026 and 2036 driven by the arrival of next-generation therapies

The interstitial lung disease market is steadily advancing with increasing adoption of conventional and supportive therapies such as corticosteroids, immunosuppressants, biologic medications, and adjunctive treatments including cough-relief agents. In parallel, innovative therapies under development, including seralutinib, L606, N-115, efzofitimod, and several others, are reshaping the treatment environment through their ability to target multiple biological pathways, ultimately fueling market progression and therapeutic advancements.

The recently released Interstitial Lung Disease Market Insights report presents an in-depth evaluation of current treatment approaches, emerging ILD therapies, therapy-wise market share, and present as well as projected market valuation spanning 2022–2036 across major regions, including the United States, EU4 nations (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

 

Interstitial Lung Disease Market Overview

·       The ILD market across the 7MM was valued at nearly USD 6 billion in 2025.

·       Among all major geographies, the United States represented the largest share of the ILD treatment market in 2025, accounting for approximately 83% compared to the EU4 countries, the UK, and Japan.

·       The total diagnosed prevalent ILD population across the 7MM reached nearly 1.3 million cases in 2025.

·       Major companies engaged in ILD drug development include GSK, Insmed, Gossamer Bio, Chiesi Farmaceutici, Liquidia Corporation, Bristol Myers Squibb, Emphycorp, aTyr Pharma, PureTech Health, Endeavor BioMedicines, Avalyn Pharma, and others.

·       Prominent ILD therapies currently under clinical investigation include Belimumab (BENLYSTA), Treprostinil Palmitil Inhalation Powder (TPIP), Seralutinib, L606 (Treprostinil Liposome Inhalation Suspension), Admilparant (BMS-986278), N115 nasal spray, Efzofitimod, Deupirfenidone (LYT-100), Taladegib (ENV-101), AP01 inhaled pirfenidone, and additional candidates. These innovative therapies are anticipated to enter the ILD market during the forecast period and significantly influence future treatment dynamics.

·       By 2036, JASCAYD (nerandomilast tablets) is expected to generate the highest revenue among ILD therapies across the 7MM.

 

Explore which segment is leading the ILD market @ Interstitial Lung Disease Market Report Sample

 

Major Drivers Supporting Interstitial Lung Disease Market Growth

Increasing Prevalence of ILDs

Growing incidence of diseases such as idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD, and occupational lung disorders continues to enlarge the global patient population.

Technological Progress in Diagnostics

Advances in high-resolution CT imaging, pulmonary function testing, and biomarker-based research are contributing to faster and more precise diagnosis of ILDs.

Greater Awareness and Screening Efforts

Improved physician education and patient awareness initiatives are supporting earlier diagnosis and increasing detection rates.

 

Introduction of Emerging ILD Therapies

The future ILD market landscape is expected to evolve substantially with the launch of therapies such as Belimumab (BENLYSTA) from GSK, TPIP from Insmed, Seralutinib from Gossamer Bio and Chiesi Farmaceutici, L606 from Liquidia Corporation, Admilparant from Bristol Myers Squibb, N115 from Emphycorp, Efzofitimod from aTyr Pharma, Deupirfenidone from PureTech Health, Taladegib from Endeavor BioMedicines, AP01 from Avalyn Pharma, and several additional pipeline candidates.

According to Ramandeep Singh, the ILD treatment pipeline is transitioning away from traditional antifibrotic and generalized immunosuppressive approaches toward targeted biologics, innovative small molecules, and sophisticated inhalation-based delivery systems. Several mid- and late-stage candidates are designed to more precisely target immune dysfunction, fibrotic signaling pathways, and pulmonary vascular remodeling. BENLYSTA from GSK demonstrates this evolution by focusing on B-cell-targeted treatment strategies for autoimmune-related ILDs such as systemic sclerosis-associated ILD and connective tissue disease-associated ILD.

 

Interstitial Lung Disease Market Assessment

Currently approved antifibrotic medications are commonly associated with gastrointestinal complications, liver-related adverse effects, and tolerability challenges, often leading to dose modification or treatment discontinuation.

The need for long-term oral administration also contributes to adherence difficulties, particularly among elderly individuals and patients with autoimmune disorders.

Furthermore, inhaled prostacyclin treatments for ILD-associated pulmonary hypertension, including TYVASO, create additional complexities because of device-dependent delivery systems.

Revenue expansion in the ILD sector is increasingly being driven by rapid adoption of premium, differentiated therapies such as OFEV and TYVASO/TYVASO DPI rather than solely by growth in disease prevalence.

The ILD pipeline remains highly diverse, incorporating next-generation antifibrotic agents, immune modulators, and lung-focused delivery technologies intended to improve efficacy, safety profiles, and phenotype-specific therapeutic outcomes.

Key advanced-stage candidates include taladegib (ENV-101), admilparant (BMS-986278), and seralutinib, along with immune-directed therapies such as belimumab and efzofitimod.

Advanced inhalation and localized drug delivery platforms such as TPIP, L606, and AP01 are specifically designed to maximize pulmonary drug exposure while reducing systemic toxicity.

Innovative approaches including N115, a nonsteroidal nasal spray, are also contributing to broader mechanistic diversification within the ILD treatment space.

 

Learn more about leading companies developing IPF therapies @ Interstitial Lung Disease Treatment Market

 

Interstitial Lung Disease Competitive Landscape

Some of the leading investigational ILD therapies currently in development include Belimumab (BENLYSTA), TPIP, Seralutinib, L606, Admilparant, N115, Efzofitimod, Deupirfenidone, Taladegib, AP01, and several additional pipeline assets.

GSK’s BENLYSTA is a B-lymphocyte stimulator (BLyS)-targeting inhibitor designed to bind soluble BLyS, a critical survival factor for B cells. As a fully human monoclonal antibody, it suppresses BLyS-mediated survival of autoreactive B cells and reduces their maturation into antibody-producing plasma cells.

Belimumab is currently undergoing Phase II/III and Phase III clinical evaluation for systemic sclerosis-associated ILD and connective tissue disease-associated ILD, underscoring the growing emphasis on B-cell-focused immunomodulatory therapies aimed at preserving lung function and reducing fibrotic progression.

Seralutinib from Gossamer Bio and Chiesi Farmaceutici is an inhaled inhibitor targeting PDGFRα/β, CSF1R, and c-KIT and is formulated as a dry-powder inhalation therapy. The therapy is being developed for pulmonary arterial hypertension and pulmonary hypertension associated with ILD.

Liquidia Corporation’s L606, created in partnership with Pharmosa Biopharm, is an investigational liposomal inhaled treprostinil formulation engineered for sustained drug release to improve pulmonary drug delivery in patients with PAH and PH-ILD.

Insmed’s TPIP is a dry-powder prodrug formulation in which treprostinil is chemically linked to a 16-carbon chain. It is being explored as a differentiated prostanoid therapy for PAH, PH-ILD, and other severe pulmonary diseases. Delivered through a capsule-based inhalation device, TPIP remains investigational and has not yet obtained approval for any indication globally.

The expected commercialization of these emerging ILD therapies is anticipated to significantly reshape the future market landscape. As regulatory approvals advance and clinical development matures, these therapies are likely to establish new treatment standards while opening avenues for medical progress and commercial growth.

 

To learn more about late-stage ILD therapies, visit @ Interstitial Lung Disease Medication Insights

 

Recent Updates in the Interstitial Lung Disease Market

·       In March 2026, United Therapeutics announced that the Phase III TETON-1 study evaluating inhaled treprostinil met its primary endpoint in patients with idiopathic pulmonary fibrosis, demonstrating meaningful improvement in forced vital capacity and reinforcing the therapy’s potential applicability beyond PH-ILD into broader ILD settings.

·       In December 2025, PureTech Health confirmed successful completion of its End-of-Phase II meeting with the US FDA regarding deupirfenidone (LYT-100) for IPF treatment.

·       In December 2025, the US FDA approved JASCAYD (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults.

·       In November 2025, Endeavor BioMedicines announced that the EMA granted PRIME designation to taladegib for IPF treatment

 

Understanding Interstitial Lung Disease

Interstitial lung disease encompasses a broad and heterogeneous category of pulmonary disorders that primarily impact the lung interstitium, the thin tissue network surrounding the alveoli. In ILD, inflammation and scarring progressively damage this tissue, decreasing lung elasticity and impairing oxygen transfer into the bloodstream.

Common causes include prolonged exposure to environmental or occupational irritants, autoimmune diseases, infections, and certain medications. In some cases, such as idiopathic pulmonary fibrosis, the underlying cause remains unidentified.

Patients with ILD often experience persistent dry cough, breathing difficulty, and fatigue, with symptoms gradually worsening over time. Although many forms of ILD are chronic and progressive, timely diagnosis and appropriate treatment can help slow disease progression and improve patient quality of life.

 

Interstitial Lung Disease Epidemiology Segmentation

The ILD epidemiology section provides insights into historical and current patient populations along with future trends across major markets. According to DelveInsight’s estimates, the United States reported nearly 520,000 diagnosed prevalent ILD cases in 2025.

The report offers epidemiological analysis for the 2022–2036 study period across the leading markets segmented into:

• Diagnosed prevalent ILD cases
• Gender-specific ILD cases
• Type-specific ILD cases
• Treated ILD cases

 

Download the report to explore top-selling pulmonary fibrosis therapies @ Interstitial Lung Disease Treatment Options

 

Interstitial Lung Disease Market Report Metrics

·       Study Period: 2022–2036

·       Coverage: 7MM (United States, EU4 countries, United Kingdom, and Japan)

·       CAGR: 8.7%

·       Market Size in 2025: USD 6 Billion

·       Key Companies: GSK, Insmed, Gossamer Bio, Chiesi Farmaceutici, Liquidia Corporation, Bristol Myers Squibb, Emphycorp, aTyr Pharma, PureTech Health, Endeavor BioMedicines, Avalyn Pharma, United Therapeutics, Boehringer Ingelheim, Roche, and others

·       Key Therapies: Belimumab (BENLYSTA), TPIP, Seralutinib, L606, Admilparant, N115, Efzofitimod, Deupirfenidone, Taladegib, AP01, TYVASO/TYVASO DPI/TREPROST, YUTREPIA, JASCAYD, OFEV, ACTEMRA, and others

 

Scope of the Interstitial Lung Disease Market Report

• Assessment of currently marketed and emerging ILD therapies
• Market dynamics and conjoint analysis of emerging ILD drugs
• Competitive intelligence analysis including SWOT evaluation and market entry strategies
• Evaluation of unmet needs, KOL perspectives, analyst insights, market access, and reimbursement landscape

 

Discover more about unmet needs in ILD treatment @ Interstitial Lung Disease Clinical Trials Insights

About DelveInsight